| Literature DB >> 35345657 |
Abstract
Cirrhosis is an active hepatic inflammation process of the liver considered as the serious phase of different liver injuries. Epidemiological studies have evaluated the possible association between TNF-α-308G/A gene polymorphism and liver cirrhosis. In this study, we have furthered the study to assess the exact association of TNF-α-308G/A gene polymorphism with liver cirrhosis susceptibility by integrating all available data. Eligible case-control studies were carried out from the establishment of the project to September 2021. Published literature from multiple databases was retrieved, collected, and analyzed by two investigators independently. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for every study. Review Manager 5.2 and Stata 15.0 software were used for meta-analysis and stability was assessed by both subgroup analysis and sensitivity analysis. Begg's funnel plot and Egger's regression across the studies were also explored. We examined 22 case-control studies with 2683 cirrhosis patients and 2905 normal controls in four genetic models (GA vs. GG: OR = 0.95, 95%CI: (0.70, 1.30); AA vs. GG: OR = 1.11, 95% CI: (0.66, 1.85), GA + AA vs. GG: OR = 1.00, 95% CI: (0.73, 1.37); AA vs. GA + GG: OR = 1.07, 95%CI: (0.70,1.63)). TNF-α-308G/A gene polymorphism was relatively independent, and the results did not show a significant difference between the two groups. In the subgroup analysis by etiological classification of liver cirrhosis, cirrhosis after HCV infection was positively associated with the risk of TNF-α-308G/A polymorphism (AA vs. GG: OR = 3.02, 95% CI: (1.15, 7.88), AA vs. GA + GG: OR = 2.68, 95% CI: (1.04, 6.95)). The meta-analysis showed TNF-α-308G/A gene polymorphism might not have affected susceptibility for liver cirrhosis. Nevertheless, further and well-designed studies were needed to confirm the findings.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35345657 PMCID: PMC8957422 DOI: 10.1155/2022/9764770
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Figure 1The flowchart of research selection.
Main characteristics of studies for meta-analysis.
| Study | Area | Ethnology | Cirrhosis type | Sample size (case and control) | Genotype case (GG/GA/AA) | Distribution case (GG/GA/AA) | NOS score (sub) |
|---|---|---|---|---|---|---|---|
| Tanaka A | Italian | European | PBC | 71/133 | 56/14/1 | 109/24/0 | 8 |
| Bahr MJ | German | European | HCV | 50/200 | 38/9/3 | 139/55/6 | 8 |
| Bathgate AJ | Scotland | European | PBC | 61/8 | 34/23/4 | 0/4/4 | 8 |
| Bernal W | England | European | PBC | 109/126 | 46/44/20 | 89/35/2 | 8 |
| Bittencourt | Brazilian | American | PBC | 57/83 | 48/9/0 | 63/19/1 | 7 |
| Jones DEJ | England | European | PBC | 168/145 | 111/53/4 | 87/49/9 | 7 |
| Juran BD | Canadian | American | PBC | 360/404 | 236/114/10 | 289/105/10 | 6 |
| Juran BD | Canadian | American | PBC | 506/357 | 24/121/361 | 12/76/269 | 6 |
| Gordon | England | European | PBC | 91/209 | 66/20/5 | 122/78/9 | 8 |
| Nguyen-Khac | French | European | ALC | 45/47 | 26/13/6 | 21/25/1 | 7 |
| NiroGA | Italian | European | PBC | 107/141 | 90/16/1 | 115/25/1 | 7 |
| Osterreicher CH | Austrian | European | HHC | 55/94 | 44/10/1 | 74/19/1 | 6 |
| Pastor | Spanish | European | ALC | 65/90 | 45/19/1 | 69/19/2 | 8 |
| Radwan | Egyptian | African | HCV | 152/160 | 108/40/4 | 136/24/0 | 8 |
| SGHAIER Ikram | Tunisians | African | HBV | 200/36 | 80/72/48 | 11/14/11 | 8 |
| Talaat | Egyptian | African | HCV | 45/45 | 25/13/7 | 39/3/3 | 8 |
| Fan | Chinese | Asian | PBC | 58/160 | 52/6/0 | 133/27/0 | 7 |
| Jiang | Chinese | Asian | HBV | 169/119 | 145/18/6 | 71/38/10 | 7 |
| LiH | Chinese | Asian | HBV | 30/40 | 23/7/0 | 38/2/0 | 6 |
| Cheng YQ | Chinese | Asian | HBV | 106/108 | 85/21/0 | 97/11/0 | 6 |
| Wu YD | Chinese | Asian | HBV | 150/150 | 96/15/39 | 84/22/44 | 7 |
| Zhang P | Chinese | Asian | HBV | 28/50 | 25/2/1 | 47/2/1 | 7 |
Summary of pooled ORs and 95%CI for TNF-α-308G/A gene polymorphism and subgroup analyses.
| (GA vs. GG) | (AA vs. GG) | (GA + AA vs. GG) | (AA vs. GA + GG) | |||||
|---|---|---|---|---|---|---|---|---|
| OR, 95% CI P, I2 | OR, 95% CI P, I2 | OR, 95% CI P, I2 | OR, 95% CI P, I2 | |||||
| Total | 0.95 (0.70,1.30) |
| 1.11 (0.66,1.85) |
| 1.00 (0.73,1.37) |
| 1.07 (0.70,1.63) |
|
| European | 0.86 (0.58,1.27) |
| 1.19 (0.42,3.37) |
| 0.93 (0.60,1.43) |
| 0.43 (0.41,4.99) |
|
| American | 0.95 (0.57,1.59) |
| 0.70 (0.28,1.77) |
| 0.91 (0.53,1.57) |
| 0.84 (0.63, 1.12) |
|
| African | 2.97 (0.56,15.64) |
| 2.08 (0.39,11.23) |
| 1.92 (0.67, 5.53) |
| 1.68 (0.44, 6.36) |
|
| Asian | 0.95 (0.38,2.35) |
| 0.60 (0.28,1.30) |
| 0.97 (0.43,2.19) |
| 0.75 (0.48, 1.18) |
|
| PBC | 0.90 (0.63,1.28) |
| 0.80 (0.22,2.88) |
| 0.90 (0.59, 1.35) |
| 0.98 (0.45, 2.10) |
|
| HCV | 1.85 (0.58,5.88) |
| 3.02 (1.15,7.88) |
| 1.96 (0.71, 5.40) |
| 2.68 (1.04, 6.95) |
|
| ALC | 0.82 (0.23,2.92) |
| 2.08 (0.34,12.73) |
| 0.95 (0.39, 2.31) |
| 2.36 (0.24, 23.38) |
|
| HBV | 0.78 (0.32,1.92) |
| 0.64 (0.41,0.99) |
| 0.98 (0.45, 2.15) |
| 0.74 (0.50, 1.10) |
|
Figure 2Forest plot of studies using a random effects model (dominant model GA vs. GG).
Figure 3Subgroup analysis by forest plot of cirrhosis type using a random effects model (dominant model AA + GA vs. GG).
Figure 4TNF- α-308G/A gene polymorphism (GA vs. GG) sensitivity analysis.
Figure 5Begg's funnel plot for publication bias in the studies (GA vs. GG).